Dylan Reid
Partner @ Zetta Venture Partners
Brooklyn, United States
Dylan Reid is a seed investor at Zetta Venture Partners in Brooklyn focused on Health Care and Biotechnology. Dylan is a partner at Zetta Venture Partners, leading investments in AI-native startups.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Dylan Reid invests in
Stages Dylan Reid invests in
Countries Dylan Reid invests in
Investment Focus
Industry
- Health Care 2 (29%)
- Biotechnology 2 (29%)
- Wellness 1 (14%)
- Biopharma 1 (14%)
- Life Science 1 (14%)
Stage
- Seed 5 (71%)
- Pre-Seed 1 (14%)
- Series A 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Jimini Health
|
Jimini’s mission is to radically improve the efficacy of mental health care across the world. Jimini has developed a novel care model that combines teletherapy sessions with personalized AI support. With Jimini, your therapy care team includes your licensed clinician and Sage, your always-available AI therapy assistant, who work together to helpyou achieve your goals.Founded in 2023 by a team of seasoned AI and biotech entrepreneurs, health tech veterans, and psychology researchers, Jimini puts science and tech first, using safe, purpose-built patient-facing technology that works exclusively under clinical oversight and high safety standards.World leaders in psychology designed Jimini’s care model to ensure that every part of the patient's journey is clinically beneficial. Jimini does not believe that LLMs should replace clinicians; rather, AI will help therapists deliver higher-quality care and focus on the most complex parts of their job. Jimini’s care model is first and foremost led by excellent clinicians.Jimini is committed to improving mental health quality and creating radically better, more modern, and clinically efficacious mental health experiences for patients. | $17M / Seed / Mar 31, 2026 | |
Boltz
|
Boltz, PBC is a public-benefit AI research company whose mission is to enable every scientist to reshape biology and create a healthier, more sustainable future. Its state-of-the-art AI models are used by leading pharmaceutical and biotech companies for biomolecular structure prediction, affinity estimation, and generative design across multiplemodalities. | $28M / Seed / Jan 08, 2026 | |
|
Jimini Health
|
Jimini’s mission is to radically improve the efficacy of mental health care across the world. Jimini has developed a novel care model that combines teletherapy sessions with personalized AI support. With Jimini, your therapy care team includes your licensed clinician and Sage, your always-available AI therapy assistant, who work together to helpyou achieve your goals.Founded in 2023 by a team of seasoned AI and biotech entrepreneurs, health tech veterans, and psychology researchers, Jimini puts science and tech first, using safe, purpose-built patient-facing technology that works exclusively under clinical oversight and high safety standards.World leaders in psychology designed Jimini’s care model to ensure that every part of the patient's journey is clinically beneficial. Jimini does not believe that LLMs should replace clinicians; rather, AI will help therapists deliver higher-quality care and focus on the most complex parts of their job. Jimini’s care model is first and foremost led by excellent clinicians.Jimini is committed to improving mental health quality and creating radically better, more modern, and clinically efficacious mental health experiences for patients. | $8M / Pre-Seed / Nov 19, 2024 | |
Noetik
|
Noetik is an AI-native biotechnology company. Noetik leverages in advanced machine learning methods to discover and develop cancer immunotherapies. | $40M / Series A / Aug 28, 2024 | |
|
Noetik
|
Noetik is an AI-native biotechnology company. Noetik leverages in advanced machine learning methods to discover and develop cancer immunotherapies. | $14M / Seed / Sep 07, 2023 | |
Nanite
|
Nanite is a non-viral gene delivery company that is developing a new class of programmable polymer nanoparticles for a variety of applications and indications. | $6M / Seed / Feb 15, 2023 | |
Nabla Bio
|
Nabla is an autoreverse platform that enables the rapid discovery of previously unattainable protein variants with supernatural qualities. Nabla Bio makes new medicines and improve nutrition by engineering novel proteins. | $11M / Seed / Dec 06, 2021 |
Co-Investors
About Zetta Venture Partners
Zetta Venture Partners is the first focused fund committed to delivering exceptional returns from the high-growth analytics market.The firm, founded by industry veteran Mark Gorenberg, launched in 2013.With offices in San Francisco and Utah, and a worldwide network of partners, entrepreneurs and investors, Zetta Venture Partners is at theforefront of the next huge and long-lasting investment opportunity.Focused funds deliver exceptional returns. In fact, over the past 10 years, focused funds have outperformed all funds by 72 basis points, according to the National Venture Capital Association. As an analytics-only fund, Zetta delivers the expertise, network and portfolio to create ongoing, exceptional deal flow.
Zetta Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
James Alcorn
Partner
|
|||
Jocelyn Goldfein
Managing Director
|
|||
Mark Gorenberg
Founder and Managing Director
|
|||
Apoorva Pandhi
Managing Director
|
|||
|
Dylan Reid
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Dylan Reid invest in?
Dylan Reid invests primarily in Health Care, Biotechnology and Wellness startups, most often at Seed and Pre-Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Dylan Reid last invest?
The most recent investment recorded for Dylan Reid closed in Mar 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
